Modeling immunotherapy of the tumor-immune interaction

被引:679
作者
Kirschner, D
Panetta, JC [1 ]
机构
[1] Penn State Univ, Behrend Coll, Sch Sci, Erie, PA 16563 USA
[2] Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA
关键词
immunotherapy; tumor; cytokine; modeling; interleukin-2; ordinary differential equations;
D O I
10.1007/s002850050127
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
A number of lines of evidence suggest that immunotherapy with the cytokine interleukin-2 (IL-2) may boost the immune system to fight tumors. CD4(+) T cells, the cells that orchestrate the immune response, use these cytokines as signaling mechanisms for immune-response stimulation as well as lymphocyte stimulation, growth, and differentiation. Because tumor cells begin as 'self', the immune system may not respond in an effective way to eradicate them. Adoptive cellular immunotherapy, can potentially restore or enhance these effects. We illustrate through mathematical modeling the dynamics between tumor cells, immune-effector cells, and IL-2. These efforts are able to explain both short tumor oscillations in tumor sizes as well as long-term tumor relapse. We then explore the effects of adoptive cellular immunotherapy on the model and describe under what circumstances the tumor can be eliminated.
引用
收藏
页码:235 / 252
页数:18
相关论文
共 38 条
[1]  
Adam J., 1996, SURVEY MODELS TUMOR
[2]  
Adam JA, 1996, MATH COMPUT MODEL, V23, P1, DOI 10.1016/0895-7177(96)00016-7
[3]   THE RELATIONSHIP OF BLOOD-TRANSFUSION, TUMOR STAGING, AND CANCER RECURRENCE [J].
BLUMBERG, N ;
CHUANGSTEIN, C ;
HEAL, JM .
TRANSFUSION, 1990, 30 (04) :291-294
[4]   Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: Results from a phase I trial in cancer patients [J].
Curti, BD ;
Ochoa, AC ;
Urba, WJ ;
Alvord, WG ;
Kopp, WC ;
Powers, G ;
Hawk, C ;
Creekmore, SP ;
Gause, BL ;
Janik, JE ;
Holmlund, JT ;
Kremers, P ;
Fenton, RG ;
Miller, L ;
Sznol, S ;
Smith, JW ;
Sharfman, WH ;
Longo, DL .
JOURNAL OF IMMUNOTHERAPY, 1996, 19 (04) :296-308
[5]  
DEBOER RJ, 1985, J IMMUNOL, V134, P2748
[6]  
DELISI C, 1977, B MATH BIOL, V39, P201, DOI 10.1016/S0092-8240(77)80008-6
[7]  
DOEDEL E, 1981, AUTO CONTINUATION BI
[8]  
ERMENTROUT GB, 1997, XPPAUT3 0 DIFFERENTI
[9]   CYCLIC LEUKOCYTOSIS IN CHRONIC MYELOGENOUS LEUKEMIA - NEW PERSPECTIVES ON PATHOGENESIS AND THERAPY [J].
GATTI, RA ;
ROBINSON, WA ;
DEINARD, AS ;
NESBIT, M ;
MCCULLOUGH, JJ ;
BALLOW, M ;
GOOD, RA .
BLOOD, 1973, 41 (06) :771-782
[10]   Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer [J].
Gause, BL ;
Sznol, M ;
Kopp, WC ;
Janik, JE ;
Smith, JW ;
Steis, RG ;
Urba, WJ ;
Sharfman, W ;
Fenton, RG ;
Creekmore, SP ;
Holmlund, J ;
Conlon, KC ;
VanderMolen, LA ;
Longo, DL .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) :2234-2241